Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

LexaGene Enters into CRADA with DoD to Foster Biothreat Detection Capabilities

by Global Biodefense Staff
September 23, 2021
Biodefense Industry News

LexaGene will work with the U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center to demonstrate the capabilities of the MiQLabTM, LexaGene’s flagship pathogen detection system, under a new Cooperative Research and Development Agreement (CRADA).

Under the agreement, LexaGene will deliver a MiQLab system to DEVCOM for the purpose of determining the system’s ability to detect Bacillus anthracis and Yersinia pestis, which cause anthrax and plague, respectively.  DEVCOM will determine the system’s sensitivity (e.g., limit-of-detection) for these two pathogens as well as evaluate the system’s quantitative detection capability.

“This CRADA enables our team to work with biothreat specialists within DEVCOM who have access to unique biothreat samples and secure government laboratory facilities,” noted Dr. Manoj Nair, Director Applications & Assay Development at LexaGene. “This working arrangement is critical for us to advance our goal of providing technology for biothreat detection to the United States government.”

The relationship with the Dr. Jack Regan, LexaGene’s CEO and Founder,

“Early in my career, I helped develop the Autonomous Pathogen Detection System (APDS), which was selected by the U.S. Department of Homeland Security to be the first autonomous detector component of their BioWatch antiterrorism program,” noted Dr. Jack Regan, LexaGene’s CEO and Founder. “Through this work, I was inspired to improve the APDS technology, so I invented the technology that LexaGene is now commercializing.”

The Select Agent research under the CRADA work will be conducted at both LexaGene and DEVCOM Chemical Biological Center at Aberdeen Proving Grounds, MD.

“LexaGene’s MiQLab is open-access, making it much more nimble for quickly responding to a novel threat. I am very pleased to be working again with the U.S. government and look forward to demonstrating to the Army the benefits of the MiQLab’s open-access technology for the rapid detection of bio-threat agents,” said Regan.

Source: LexaGene

Tags: AnthraxBioWatchECBCEditor PickSelect AgentsY. pestis

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC